Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | -$5.24 | $0.16 | -$0.74 |
Q2 2024 | 2 | -$7.11 | $0.21 | -$1.00 |
Q3 2024 | 1 | -$7.14 | $0.21 | -$1.00 |
Q4 2024 | 5 | -$1.35 | -$0.94 | -$1.13 |
Q1 2025 | 2 | -$1.14 | -$0.81 | -$0.98 |
Q2 2025 | 1 | -$7.29 | $0.22 | -$1.02 |
Q3 2025 | 1 | -$7.15 | $0.21 | -$1.00 |
Q4 2025 | 1 | -$6.75 | $0.20 | -$0.95 |
Q1 2026 | 1 | -$6.91 | $0.20 | -$0.97 |
Q2 2026 | 1 | -$4.63 | $0.14 | -$0.65 |
Q3 2026 | 1 | -$5.77 | $0.17 | -$0.81 |
Q4 2026 | 1 | -$5.41 | $0.16 | -$0.76 |
BridgeBio Pharma, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.86 earnings per share for the quarter, topping analysts' consensus estimates of $-1.03 by $0.17. The company had revenue of 2.73 M for the quarter and had revenue of 9.30 M for the year. BridgeBio Pharma, Inc. has generated $-4 earnings per share over the last year ($-3.95 diluted earnings per share) and currently has a price-to-earnings ratio of -11.83. BridgeBio Pharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
09/30/2024 | Q3 2024 | -$0.86 | $1.68 M | $2.73 M | ||
08/01/2024 | Q2 2024 | -$1.09 | -$0.39 | 0.7 | $3.96 M | $2.17 M |
05/02/2024 | Q1 2024 | -$0.40 | -$0.20 | 0.2 | $211.12 M | |
02/22/2024 | Q4 2023 | -$0.95 | -$0.96 | -0.01 | $1.75 M | |
11/02/2023 | Q3 2023 | -$0.86 | -$1.08 | -0.22 | $3.62 M | $4.09 M |
08/03/2023 | Q2 2023 | -$0.86 | -$0.98 | -0.12 | $2.99 M | $1.64 M |
05/04/2023 | Q1 2023 | -$0.84 | -$1.16 | -0.32 | $1.83 M | |
02/23/2023 | Q4 2022 | -$0.86 | -$1.04 | -0.18 | $1.87 M | |
11/03/2022 | Q3 2022 | -$1.02 | -$1.00 | 0.02 | $4.09 M | $338,000 |
08/04/2022 | Q2 2022 | -$0.92 | $0.40 | 1.32 | $27.19 M | $73.75 M |
05/05/2022 | Q1 2022 | -$1.13 | -$1.69 | -0.56 | $1.69 M | |
02/25/2022 | Q4 2021 | -$1.01 | $12.89 M | |||
11/04/2021 | Q3 2021 | -$0.91 | -$1.06 | -0.15 | $15.80 M | $2.34 M |
08/05/2021 | Q2 2021 | -$0.93 | -$0.66 | 0.27 | $28.49 M | $54.02 M |
05/06/2021 | Q1 2021 | -$0.87 | -$1.18 | -0.31 | $462,000 | |
02/25/2021 | Q4 2020 | -$0.86 | -$1.01 | -0.15 | $122,000 | |
11/05/2020 | Q3 2020 | -$0.97 | -$0.98 | -0.01 | $10.75 M | $8.13 M |
08/11/2020 | Q2 2020 | -$0.79 | -$1.03 | -0.24 | $0 | |
05/13/2020 | Q1 2020 | -$0.78 | $0 | |||
03/03/2020 | Q4 2019 | -$0.62 | $13.82 M |
BridgeBio Pharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 20th, 2025 based off last year's report dates.
In the previous quarter, BridgeBio Pharma, Inc. (:BBIO) reported $-0.86 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.03 by $0.17.
The conference call for BridgeBio Pharma, Inc.'s latest earnings report can be listened to online.
The conference call transcript for BridgeBio Pharma, Inc.'s latest earnings report can be read online.
BridgeBio Pharma, Inc. (:BBIO) has a recorded annual revenue of $9.30 M.
BridgeBio Pharma, Inc. (:BBIO) has a recorded net income of $9.30 M. BridgeBio Pharma, Inc. has generated $-3.95 earnings per share over the last four quarters.
BridgeBio Pharma, Inc. (:BBIO) has a price-to-earnings ratio of -11.83 and price/earnings-to-growth ratio is -1.41.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED